CD19 and lymphoma: In phase I and II trials with patients of CD19+ lymphoid cancers, the CAR-NK cells showed positive responses without the induction of toxic effects associated with CAR-T cell therapy, namely cytokine release syndrome and neurologic toxic effects, although they did observe high-grade transient myelotoxicity [167,170].